Abyntek Biopharma | Bioreactivos’ Post

Sequence and Configuration of a Novel Bispecific Antibody Format Impacts Its Production Using Chinese Hamster Ovary (CHO) Cells Here, we describe the impact of the sequence and configuration of a unique bispecific antibody format (termed BYbe) using a panel of four BYbe's and the three IgG1s from which they were derived on their production in a Chinese hamster ovary (CHO) cell expression system. Following transfection and selection, one bispecific antibody format yielded fewer mini pools in comparison to the other bispecific cell pools. When the top 12 expressing stable mini pools of all BYbe configurations and sequences were evaluated, both the dsscFv sequence and antibody chain configuration or placement directly impacted productivity. The cell-specific productivity (qP, pg/cell/day) was lower in all BYbe cell pools compared to the IgG1 cell lines. However, when the actual molecules/cell/day produced were considered, three of the four bispecific cell pools outproduced the parental IgG1 cell pools. https://lnkd.in/gRM248Zm #aspenalert #biotech #bioprocess

Thoughts on this? >> Engineered Cas clears barrier to antiviral CRISPR therapies - LabPulse >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #pharmaceutical #competitivemarketing #healthcare

Thoughts on this? >> Engineered Cas clears barrier to antiviral CRISPR therapies - LabPulse >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #pharma #biotech #healthcare

This new open access review article is entitled “Generation of binder-format-payload conjugate-matrices by antibody chain-exchange” and looks very interesting to us. The following is the abstract of this paper: “The generation of antibody-drug conjugates with optimal functionality depends on many parameters. These include binder epitope, antibody format, linker composition, conjugation site(s), drug-to-antibody ratio, and conjugation method. The production of matrices that cover all possible parameters is a major challenge in identifying optimal antibody-drug conjugates. To address this bottleneck, we adapted our Format Chain Exchange technology (FORCE), originally established for bispecific antibodies, toward the generation of binder-format-payload matrices (pair-FORCE). Antibody derivatives with exchange-enabled Fc-heterodimers are combined with payload-conjugated Fc donors, and subsequent chain-exchange transfers payloads to antibody derivatives in different formats. The resulting binder-format-conjugate matrices can be generated with cytotoxic payloads, dyes, haptens, and large molecules, resulting in versatile tools for ADC screening campaigns. We show the relevance of pair-FORCE for identifying optimal HER2-targeting antibody-drug conjugates. Analysis of this matrix reveals that the notion of format-defines-function applies not only to bispecific antibodies, but also to antibody-drug conjugates.” The corresponding author of this excellent paper is the prestigious Dr. Ulrich Brinkmann at Roche Pharma Research and Early Development (pRED). Open access to this paper at: https://lnkd.in/eE95n464 Chinese Antibody Society and its official journal, Antibody Therapeutics jointly organize 2024 mAbTalk Symposium on December 15 in San Diego with the theme of “AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates”. You are welcome to know more information about this symposium and register for it via the following link. https://lnkd.in/gjCEAVxM #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics #adc #adcs #antibodydrugconjugates #antibodydrugconjugate

Downstream purification plays a pivotal role in ensuring the safety and efficacy of antibody therapeutics. HIC emerges as a crucial technology within antibody therapeutic polishing. This technique effectively removes process- and product-related impurities, including host cell proteins (HCPs), residual DNA, and antibody variants, facilitating the production of high-purity drug products that meet regulatory requirements. Key advantages of HIC in antibody polishing: ◾Targeted Impurity Removal: HIC selectively captures impurities based on their hydrophobicity, resulting in a highly purified antibody therapeutic. ◾Scalability for Large-Scale Manufacturing: The technique effortlessly adapts to large-scale biomanufacturing processes. ◾Achieving High Purity Standards: HIC significantly contributes to attaining the stringent purity levels demanded for safe and effective antibody drugs. Learn More: https://lnkd.in/gC9bQFR4 #antibodytherapeutics #HIC #downstreamprocessing #biomanufacturing

Thoughts on this? >> Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells - CGTLive™ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #competitivemarketing #pharma

In a recently posted pre-print, Merck authors and colleagues report new results for their PROxAb Shuttle technology, enabling targeted delivery of proteolysis-targeting chimeras (PROTACs) using antibodies fused with PROTAC-binding domains derived from camelid single-domain antibodies (VHHs). From the abstract: Here, a modular approach to quickly generate PROxAb Shuttles by enzymatically coupling PROTAC-binding VHHs to off-the-shelf antibodies was developed. The resulting conjugates retained their target binding and internalization properties and incubation with BRD4-targeting PROTACs resulted in formation of defined PROxAb-PROTAC complexes. These complexes selectively induced degradation of the BRD4 protein, resulting in cytotoxicity specifically in cells expressing the antibodies target. The chemoenzymatic approach described here provides a versatile and efficient solution for generating antibody-VHH conjugates for targeted protein degradation applications but could also be used to combine antibody and VHH binders to generate bispecific antibodies for further applications. https://lnkd.in/e5fesghP

Hot off the press 🔥 A long-awaited Epi-paper was published today in #mAbs! Check out this review of the #ISPRI Toolkit - complete with relevant case studies detailing how crucial conducting preclinical immunogenicity assessments at different stages of development can be to de-risking your biologics pipeline. Want to see ISPRI in action? Join us at the AI / HI & Immunoinformatics Summit in June! https://lnkd.in/eCkHkz8B #bioinformatics #AI #immunogenicity

The market for bispecific antibodies is growing, creating opportunities for pharma and biotech companies. However, an understanding of bsAbs is required before organisations can start their journey. In this blog post, our own Desmond Schofield explores what bsAbs are, their history, and future prospects for the sector. If you're ready to start exploring the therapeutic potential of these antibodies, the later sections detail how evitria can support you or you can simply get in touch with our team today. #Antibodies #BispecificAntibodies #Biotech #Biopharma

📣 📣 📣 Hello everyone, #Dot2024 commences today! Alphelix is eager to connect with you all!  📢 Poster No. B04, titled “Premium Proteins and Cryo-EM Structures with Novel Technology for GPCR Drug Discovery,” invites those interested in #GPCR drug discovery to stop by.   📢 Booth No. 425 welcomes you to engage with our Business Development Team!  #Alphelix Biosciences is a biotechnology company dedicated to the early discovery of GPCR therapeutics. Leveraging several world-leading GPCR technology platforms with proprietary intellectual property, we offer global innovative pharmaceutical companies comprehensive services ranging from #GPCR protein preparation and structural elucidation to the early-stage discovery of antibodies, small molecules, and peptide therapeutics.  We maintain the world’s largest library of purified, #ligand-free GPCR proteins, which are exceptionally suitable for #DEL screening, #AS-MS screening, #antibody discovery/screening, and ligand affinity measurements.  Additionally, we have developed a proprietary GPCR antibody development platform, MegAb, to address various challenges encountered in GPCR antibody development.  We invite companies interested in pioneering technologies for GPCR drug development to visit our booth or connect with us online! #GPCR #DrugDiscovery #DOT2024 #DEL #Antibody Discovery #GPR75 #VIP2R #Peptide library #Small molecules #Metabolism #Autoimmunity #Cancer